The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents
- 1 December 2015
- journal article
- Published by Elsevier in Neuropharmacology
- Vol. 99, 256-263
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Pharmacological approaches to treating negative symptoms: A review of clinical trialsSchizophrenia Research, 2013
- Current Landscape of Phosphodiesterase 10A (PDE10A) InhibitionJournal of Medicinal Chemistry, 2012
- Differential regulation of motor control and response to dopaminergic drugs by D1R and D2R neurons in distinct dorsal striatum subregionsThe EMBO Journal, 2011
- Biochemistry and Physiology of Cyclic Nucleotide Phosphodiesterases: Essential Components in Cyclic Nucleotide SignalingAnnual Review of Biochemistry, 2007
- Immunohistochemical Localization of Phosphodiesterase 10A in Multiple Mammalian SpeciesJournal of Histochemistry & Cytochemistry, 2006
- Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical UsePharmacological Reviews, 2006
- Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studiesEuropean Psychiatry, 2005
- D1 dopamine receptor stimulation increases GluR1 phosphorylation in postnatal nucleus accumbens culturesJournal of Neurochemistry, 2002
- The functional anatomy of basal ganglia disordersTrends in Neurosciences, 1989
- Antipsychotic Drugs, Neurotransmitters, and SchizophreniaAmerican Journal of Psychiatry, 1978